FierceBiotech Radio at #BIO2015

FierceBiotech Radio is back with a two-part special from the BIO conference in Philadelphia.

In Part I, FierceBiotech Editor-in-Chief John Carroll moderates a discussion on cancer R&D, featuring leaders from AstraZeneca, Juno Therapeutics, Merck, Johnson & Johnson and GlaxoSmithKline. Catch video of the event here.

And in Part II, Damian Garde takes the pulse of the conference, talking to executives from Roche, uniQure, Alexandria Real Estate and Egalet.

Download the episodes on iTunes or Stitcher, or listen below--and be sure to subscribe. Let us know what you think by dropping a line to [email protected]

Part I:

Part II:

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

ATAI Life Sciences is topping off a busy year with a $125 million financing, which will push two programs through phase 2 readouts.

After more than a decade working on heart failure programs with Cytokinetics, Amgen is handing two programs back to its partner.